Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Oct 27, 2022; 14(10): 1150-1160
Published online Oct 27, 2022. doi: 10.4240/wjgs.v14.i10.1150
Published online Oct 27, 2022. doi: 10.4240/wjgs.v14.i10.1150
Characteristic | All cases (n = 82) | True group (n = 48) | Pseudo-group (n = 34) | P value | |
Age range (yr) | 55 ± 12 | 50 ± 16 | 53 ± 14 | 0.745 | |
Male/female (n) | 46/30 | 26/18 | 20/12 | 0.402 | |
AFP (ng/mL) (+/-) | 49/33 | 47/1 | 2/32 | 0.001 | |
Tumor-related characteristics | |||||
Tumor size (cm) | 4.0 ± 1.8 | 4.2 ± 1.6 | 2.7 ± 1.3 | 0.142 | |
Enhancement (+/-) | 50/32 | 46/2 | 4/30 | 0.006 | |
DSA (+/-) | 42/27 | 42/2 | 0/25 | < 0.010 | |
Resection (+/-) | 10 | 9 | 1 | - | |
TACE times (single/repeated) | 26/56 | 4/44 | 22/12 | < 0.011 | |
Follow-up for > 6 mo (+/-) | 39/33 | 39/0 | 0/33 | < 0.001 |
MK | MD | KA | KR | DA | DR | FAk | |
ROI (T) | 0.86 | 0.85 | 0.80 | 0.83 | 0.76 | 0.78 | 0.62 |
ROI (N) | 0.79 | 0.74 | 0.71 | 0.76 | 0.72 | 0.75 | 0.54 |
ROI (F) | 0.70 | 0.73 | 0.69 | 0.68 | 0.64 | 0.70 | 0.50 |
MK | MD | KR | KA | DR | DA | FAk | |
N | 0.60 ± 0.15 | 1.90 ± 0.65 | 0.55 ± 0.16 | 0.60 ± 0.13 | 1.88 ± 0.55 | 2.20 ± 0.63 | 0.10 ± 0.09 |
Y | 0.71 ± 0.24 | 1.60 ± 0.45 | 0.65 ± 0.29 | 0.70 ± 0.15 | 1.4 ± 0.38 | 2.10 ± 0.60 | 0.32 ± 0.22 |
Std-N | 0.68 ± 0.27 | 1.89 ± 0.58 | 0.70 ± 0.31 | 0.61 ± 0.16 | 2.01 ± 0.54 | 1.60 ± 0.42 | 0.54 ± 0.32 |
Std-Y | 0.81 ± 0.23 | 0.91 ± 0.18 | 0.75 ± 0.24 | 1.03 ± 0.20 | 0.88 ± 0.22 | 0.92 ± 0.22 | 1.07 ± 0.78 |
P value | 0.270 | 0.009 | 0.679 | 0.000 | 0.003 | 0.000 | 0.000 |
- Citation: Cao X, Shi H, Dou WQ, Zhao XY, Zheng YX, Ge YP, Cheng HC, Geng DY, Wang JY. Can DKI-MRI predict recurrence and invasion of peritumoral zone of hepatocellular carcinoma after transcatheter arterial chemoembolization? World J Gastrointest Surg 2022; 14(10): 1150-1160
- URL: https://www.wjgnet.com/1948-9366/full/v14/i10/1150.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i10.1150